Key facts
- Gibson Oncology’s last known valuation is $35.0M (Jul 2025).
- It has raised $8.0M across 2 recorded rounds; the latest was Seed Round ($250K) in Jul 2025.
- Notable investors include Individuals' Venture Fund.
- Gibson Oncology has filed 2 Form Ds with the SEC since 2024, most recently Jul 2025 ($250K sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Gibson Oncology
Funding rounds
2 roundsAbout Gibson Oncology
Developer of a clinical-stage oncology platform designed to develop dual-targeted small molecules that inhibit topoisomerase I and the cMyc oncogene. The company offers proprietary Indenoisoquinoline and Azaindenoisoquinoline compounds with mechanisms of action to overcome resistance to older cancer agents, enabling researchers and clinicians to explore treatment options for solid tumors and lymphomas, including glioblastoma.
- Sector
- Healthcare
- HQ
- Miami, FL, United States
- Founded
- 2018
- Employees
- 2
- Website
- gibsononcology.com/
- Ownership
- Privately Held (backing)
Gibson Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gibson Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gibson Oncology in its N-PORT filings yet. We sweep new filings monthly.